HK1204302A1 - 癌症免疫療法的組合物和方法 - Google Patents
癌症免疫療法的組合物和方法Info
- Publication number
- HK1204302A1 HK1204302A1 HK15104847.0A HK15104847A HK1204302A1 HK 1204302 A1 HK1204302 A1 HK 1204302A1 HK 15104847 A HK15104847 A HK 15104847A HK 1204302 A1 HK1204302 A1 HK 1204302A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- cancer immunotherapy
- immunotherapy
- cancer
- Prior art date
Links
- 238000002619 cancer immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/001139—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261657574P | 2012-06-08 | 2012-06-08 | |
PCT/US2013/044744 WO2013185052A1 (en) | 2012-06-08 | 2013-06-07 | Compostions and methods for cancer immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1204302A1 true HK1204302A1 (zh) | 2015-11-13 |
Family
ID=49712686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104847.0A HK1204302A1 (zh) | 2012-06-08 | 2015-05-21 | 癌症免疫療法的組合物和方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US9770467B2 (zh) |
EP (1) | EP2858722B8 (zh) |
JP (1) | JP6257607B2 (zh) |
KR (1) | KR20150022996A (zh) |
CN (1) | CN104507538B (zh) |
AU (1) | AU2013271375B2 (zh) |
CA (1) | CA2876150A1 (zh) |
HK (1) | HK1204302A1 (zh) |
IN (1) | IN2014MN02492A (zh) |
NZ (1) | NZ702392A (zh) |
SG (2) | SG10201610251PA (zh) |
WO (1) | WO2013185052A1 (zh) |
Families Citing this family (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック,インコーポレイテッド | 癌免疫療法のための組成物および方法 |
AU2013358892B2 (en) | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
PL2934598T3 (pl) * | 2012-12-19 | 2018-10-31 | Board Of Regents, The University Of Texas System | Środek farmaceutyczny ukierunkowany na ssaczy szlak przekazywania sygnału przez cykliczne dinukleotydy |
TN2015000457A1 (en) | 2013-04-29 | 2017-04-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
US20140329889A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
AU2014268836B2 (en) * | 2013-05-18 | 2018-08-02 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
EP2996472B1 (en) * | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
WO2014198862A1 (en) * | 2013-06-14 | 2014-12-18 | Intervet International B.V. | Pharmaceutical compositions comprising a gpg oligodeoxynucleotide and cyclic di-gmp |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
GEP20237496B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
US10421971B2 (en) * | 2014-01-15 | 2019-09-24 | The University Of Chicago | Anti-tumor therapy |
US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
CN103908468B (zh) * | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
KR20170015353A (ko) | 2014-06-04 | 2017-02-08 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Sting의 조절제로서 사이클릭 디뉴클레오타이드 |
WO2016040313A2 (en) * | 2014-09-08 | 2016-03-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancer |
US10010607B2 (en) | 2014-09-16 | 2018-07-03 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response |
US11236139B2 (en) * | 2014-11-05 | 2022-02-01 | The Regents Of The University Of California | Combination immunotherapy |
JP6762030B2 (ja) * | 2014-11-20 | 2020-09-30 | 国立研究開発法人医薬基盤・健康・栄養研究所 | 異なる核酸アジュバントの組み合わせによる、新規Th1誘導性アジュバントおよびその用途 |
WO2016096577A1 (en) * | 2014-12-16 | 2016-06-23 | Invivogen | Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment |
PL3233882T3 (pl) | 2014-12-16 | 2020-04-30 | Kayla Therapeutics | Fluorowane cykliczne dinukleotydy do indukcji cytokin |
GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
WO2016130616A1 (en) * | 2015-02-11 | 2016-08-18 | The Johns Hopkins University | Bacteria over-expressing c-di-amp and therapeutic methods |
US20180127717A1 (en) * | 2015-05-07 | 2018-05-10 | Baylor College Of Medicine | Dendritic cell immunotherapy |
UA123701C2 (uk) | 2015-08-13 | 2021-05-19 | Мерк Шарп І Доум Корп. | Циклічні динуклеотидні сполуки як агоністи sting |
US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
CN106540255A (zh) * | 2015-09-18 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP联合贝伐珠单抗在抗肿瘤中的应用 |
CN106540254A (zh) * | 2015-09-22 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 环二核苷酸cGAMP及其衍生物是潜在免疫佐剂 |
CN106540253A (zh) * | 2015-09-24 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | cGAMP及其衍生物在制备抗肿瘤疫苗中的应用 |
CN105367617A (zh) * | 2015-09-25 | 2016-03-02 | 武汉品生科技有限公司 | 一种基于环二腺核苷酸的衍生物、tat多肽及其在一型干扰素小分子中抑制剂的应用 |
RU2722019C2 (ru) | 2015-12-03 | 2020-05-26 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
US10604542B2 (en) | 2016-01-11 | 2020-03-31 | Innate Tumor Immunity, Inc. | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer |
CN106544319A (zh) * | 2016-01-24 | 2017-03-29 | 聊城市奥润生物医药科技有限公司 | 一种用于刺激树突状细胞成熟的组合物及其用于刺激树突状细胞成熟的方法 |
WO2017157437A1 (en) | 2016-03-16 | 2017-09-21 | Institut Curie | Method for preparing viral particles with cyclic dinucleotide and use of said particles for treating cancer |
CA3017524A1 (en) * | 2016-03-18 | 2017-09-21 | Immune Sensor, Llc | Cyclic di-nucleotide compounds and methods of use |
IL295649A (en) | 2016-04-07 | 2022-10-01 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides are useful as protein modulators |
RU2018137389A (ru) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
EP3481402A4 (en) | 2016-07-06 | 2020-01-22 | Sperovie Biosciences, Inc. | CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE |
KR102497742B1 (ko) | 2016-08-30 | 2023-02-10 | 다나-파버 캔서 인스티튜트 인크. | 약물 전달 조성물 및 그의 용도 |
EA037513B1 (ru) * | 2016-09-17 | 2021-04-06 | ИММЬЮН СЕНСОР, ЭлЭлСи | Циклические динуклеотидные соединения и способы их применения |
BR112019006816A8 (pt) | 2016-10-04 | 2023-02-07 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting, composição farmacêutica e uso dos mesmos |
JOP20170192A1 (ar) | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
KR101889181B1 (ko) * | 2016-12-19 | 2018-08-16 | 주식회사 포스코 | 굽힘성 및 신장플랜지성이 우수한 고장력강 및 이의 제조방법 |
JP2020504745A (ja) * | 2016-12-22 | 2020-02-13 | マブファーマ,インク. | I型ifn産生を増強または増大する組成物および方法 |
BR112019015797A2 (pt) | 2017-02-01 | 2020-03-17 | Modernatx, Inc. | Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação |
US20200055883A1 (en) * | 2017-02-17 | 2020-02-20 | Eisai R&D Management Co., Ltd. | Cyclic di-nucleotides derivative for the treatment of cancer |
US10933078B2 (en) | 2017-02-21 | 2021-03-02 | Board Of Regents, The University Of Texas System | Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
US11629346B2 (en) * | 2017-06-12 | 2023-04-18 | University Of Miami | Sting-dependent activators for treatment of disease |
US11969499B2 (en) | 2017-06-16 | 2024-04-30 | William Marsh Rice University | Hydrogel delivery of sting immunotherapy for treatment cancer |
JP2020529421A (ja) | 2017-08-04 | 2020-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | がんの処置のためのPD−1アンタゴニストおよびベンゾ[b]チオフェンSTINGアゴニストの組み合わせ |
AU2018311966A1 (en) | 2017-08-04 | 2020-02-13 | Merck Sharp & Dohme Llc | Benzo[b]thiophene sting agonists for cancer treatment |
US11638716B2 (en) | 2017-08-31 | 2023-05-02 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
CN107619438B (zh) * | 2017-10-11 | 2021-12-03 | 广州云启科技有限公司 | 新型环二核苷酸受体及其激动剂或抑制剂筛选的方法和试剂盒 |
CN109694397B (zh) * | 2017-10-23 | 2021-08-31 | 上海弘翊生物科技有限公司 | 环状二核苷酸化合物、其制备方法和应用 |
CN111566119A (zh) | 2017-11-10 | 2020-08-21 | 武田药品工业有限公司 | Sting调节剂化合物以及制备和使用方法 |
CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
WO2019125974A1 (en) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Cyclic di-nucleotide compounds as sting agonists |
JP2021518386A (ja) | 2018-03-23 | 2021-08-02 | コディアック バイオサイエンシーズ, インコーポレイテッド | Stingアゴニストを含む細胞外小胞 |
WO2019195063A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
CA3095646A1 (en) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophenes and related compounds as sting agonists |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
US11691990B2 (en) | 2018-08-16 | 2023-07-04 | Eisai R&D Management Co., Ltd | Salts of compounds and crystals thereof |
EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
US20210355546A1 (en) * | 2018-11-02 | 2021-11-18 | The Regents Of The University Of California | Methods to Diagnose and Treat Cancer Using Non-Human Nucleic Acids |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
MX2021011241A (es) | 2019-03-21 | 2022-01-19 | Codiak Biosciences Inc | Vesiculas extracelulares para administracion de vacunas. |
CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
TW202104214A (zh) | 2019-04-05 | 2021-02-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 化合物 |
MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
EP3966222A4 (en) | 2019-05-09 | 2023-10-04 | Aligos Therapeutics, Inc. | MODIFIED CYCLIC DI-NUCLEOSIDE COMPOUNDS AS STING MODULATORS |
WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
MX2022002144A (es) * | 2019-08-21 | 2022-05-13 | Scripps Research Inst | Agonistas monocíclicos de estimulador de genes interferón sting. |
WO2021041532A1 (en) | 2019-08-26 | 2021-03-04 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
WO2021062060A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
WO2021189047A2 (en) | 2020-03-20 | 2021-09-23 | Codiak Biosciences, Inc. | Extracellular vesicles for therapy |
US20230225972A1 (en) * | 2020-04-15 | 2023-07-20 | Statens Serum Institut | Liposomal composition for preventing or early treatment of pathogenic infection |
US20230149560A1 (en) | 2020-04-20 | 2023-05-18 | Massachusetts Institute Of Technology | Lipid compositions for delivery of sting agonist compounds and uses thereof |
US11897888B1 (en) | 2020-04-30 | 2024-02-13 | Stinginn Llc | Small molecular inhibitors of sting signaling compositions and methods of use |
WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
JP7072604B2 (ja) * | 2020-06-23 | 2022-05-20 | アンスティテュ・クリー | 環状ジヌクレオチドを含むウイルス粒子を調製する方法及びがんを治療するための前記粒子の使用 |
CN111956797B (zh) * | 2020-07-10 | 2022-05-13 | 清华大学 | 新型疫苗佐剂及其在新冠肺炎疫苗和其他疫苗中的应用 |
US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
US20220168330A1 (en) | 2020-11-09 | 2022-06-02 | Takeda Pharmaceutical Company Limited | Antibody drug conjugates |
WO2022118043A1 (en) * | 2020-12-03 | 2022-06-09 | Enara Bio Limited | Novel protein-ligand complex |
WO2022223619A1 (en) | 2021-04-20 | 2022-10-27 | Institut Curie | Compositions and methods for use in immunotherapy |
EP4326321A1 (en) | 2021-04-20 | 2024-02-28 | Institut Curie | Compositions and methods for use in immunotherapy |
WO2023056468A1 (en) | 2021-09-30 | 2023-04-06 | Codiak Biosciences, Inc. | Extracellular vesicle comprising cholesterol tagged sting-agonist |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9110808D0 (en) | 1991-05-17 | 1991-07-10 | Retroscreen Ltd | Aids vaccine and method for its production |
GB2257704B (en) | 1991-07-18 | 1995-03-01 | Erba Carlo Spa | Cyclic oligonucleotides phosphorothioates |
US5637483A (en) * | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
IT1262895B (it) | 1992-03-02 | 1996-07-22 | Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico. | |
US5635160A (en) | 1995-06-07 | 1997-06-03 | The University Of North Carolina At Chapel Hill | Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions |
US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
ES2218994T3 (es) | 1998-02-02 | 2004-11-16 | The Johns Hopkins University School Of Medicine | Linea celular inmunomoduladora universal que expresa citocinas y composiciones relacionadas y procedimientos de fabricacion y uso. |
CA2359674A1 (en) | 1999-02-15 | 2000-08-17 | Nippon Shinyaku Co., Ltd. | Chain-shortened polynucleotide and method for preparation thereof |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
ES2265948T3 (es) | 1999-06-14 | 2007-03-01 | Cancer Research Technology Limited | Terapia para el cancer. |
US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
AU2001290860A1 (en) | 2000-09-21 | 2002-04-02 | The Regents Of The University Of California | Spas-1 cancer antigen |
WO2002059575A2 (en) | 2001-01-23 | 2002-08-01 | The Trustees Of Princeton University, Princeton University | Method and apparatus for analysis of biological solutions |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
AR040996A1 (es) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | Acidos nucleicos inmunoestimuladores |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
WO2005030186A2 (en) | 2003-07-28 | 2005-04-07 | Univ Maryland | Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
EP1682173A4 (en) | 2003-10-15 | 2007-10-31 | Medimmune Inc | EPHA2 VACCINE ON LISTERIA BASE |
KR20060123170A (ko) | 2003-10-24 | 2006-12-01 | 알자 코포레이션 | 지질 입자의 제조방법 |
US7592326B2 (en) * | 2004-03-15 | 2009-09-22 | Karaolis David K R | Method for stimulating the immune, inflammatory or neuroprotective response |
AU2005222626B2 (en) | 2004-03-15 | 2010-05-20 | Karagen Pharmaceuticals, Inc. | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
CA2607579A1 (en) | 2005-05-06 | 2006-11-23 | The Regents Of The University Of California | Microfluidic system for identifying or sizing individual particles passing through a channel |
US20070059683A1 (en) | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
WO2007064945A2 (en) | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
WO2008030887A2 (en) | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Methods for designing parp inhibitors and uses thereof |
WO2009133560A1 (en) | 2008-04-29 | 2009-11-05 | Smart Assays | Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof |
WO2010017248A2 (en) | 2008-08-04 | 2010-02-11 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
US8840881B2 (en) | 2008-08-28 | 2014-09-23 | Aduro Gvax Inc. | Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer |
RU2477753C2 (ru) | 2008-12-09 | 2013-03-20 | Коули Фармасьютикал Груп, Инк. | Иммуностимулирующие олигонуклеотиды |
US8765171B2 (en) | 2009-03-09 | 2014-07-01 | The Regents Of The University Of California | Methods and compositions for liposomal formulation of antigens and uses thereof |
US8414630B2 (en) | 2009-03-10 | 2013-04-09 | Marc Evan Richelsoph | Active bone screw |
US8722064B2 (en) | 2009-06-05 | 2014-05-13 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
US20120178710A1 (en) | 2009-07-01 | 2012-07-12 | Rutgers, The State University Of New Jersey | Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof |
US8771933B2 (en) | 2009-10-06 | 2014-07-08 | Massachusetts Institute Of Technology | Continuous-flow deformability-based cell separation |
US20110289043A1 (en) | 2010-03-22 | 2011-11-24 | Brown University Research Foundation | Computational methods and compositions |
WO2011136828A1 (en) * | 2010-04-27 | 2011-11-03 | The Johns Hopkins University | Immunogenic compositions and methods for treating neoplasia |
US8450293B2 (en) | 2010-08-10 | 2013-05-28 | Rutgers, The State University Of New Jersey | Synthesis and characterization of C8 analogs of c-di-GMP |
DK2640842T3 (en) | 2010-11-17 | 2018-08-13 | Aduro Biotech Inc | Methods and compositions for inducing an immune response to EGFRVIII |
US9061048B2 (en) | 2010-12-15 | 2015-06-23 | The Regents Of The University Of California | Cyclic di-AMP induction of type I interferon |
EP2655392B1 (en) | 2010-12-22 | 2018-04-18 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
CA2833026A1 (en) | 2011-04-15 | 2012-10-18 | The University Of British Columbia | Method and apparatus for separation of particles |
WO2013086331A1 (en) | 2011-12-07 | 2013-06-13 | President And Fellows Of Harvard College | High efficiency di-nucleotide cyclase |
EP2844756A4 (en) | 2012-04-30 | 2016-02-24 | Glen N Barber | MODULATION OF IMMUNE REACTIONS |
JP6257607B2 (ja) | 2012-06-08 | 2018-01-10 | アデュロ バイオテック,インコーポレイテッド | 癌免疫療法のための組成物および方法 |
US9090646B2 (en) | 2012-12-05 | 2015-07-28 | Rutgers, The State University Of New Jersey | Biotinylated compounds |
AU2013358892B2 (en) | 2012-12-13 | 2018-06-21 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
PL2934598T3 (pl) | 2012-12-19 | 2018-10-31 | Board Of Regents, The University Of Texas System | Środek farmaceutyczny ukierunkowany na ssaczy szlak przekazywania sygnału przez cykliczne dinukleotydy |
TN2015000457A1 (en) | 2013-04-29 | 2017-04-06 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
US20140329889A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
AU2014268836B2 (en) | 2013-05-18 | 2018-08-02 | Aduro Biotech, Inc. | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
US9549944B2 (en) | 2013-05-18 | 2017-01-24 | Aduro Biotech, Inc. | Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling |
WO2015017652A1 (en) | 2013-07-31 | 2015-02-05 | Memorial Sloan-Kettering Cancer Center | Sting crystals and modulators |
-
2013
- 2013-06-07 JP JP2015516245A patent/JP6257607B2/ja not_active Expired - Fee Related
- 2013-06-07 SG SG10201610251PA patent/SG10201610251PA/en unknown
- 2013-06-07 CN CN201380037917.2A patent/CN104507538B/zh not_active Expired - Fee Related
- 2013-06-07 CA CA2876150A patent/CA2876150A1/en not_active Abandoned
- 2013-06-07 NZ NZ702392A patent/NZ702392A/en not_active IP Right Cessation
- 2013-06-07 IN IN2492MUN2014 patent/IN2014MN02492A/en unknown
- 2013-06-07 SG SG11201407875UA patent/SG11201407875UA/en unknown
- 2013-06-07 AU AU2013271375A patent/AU2013271375B2/en not_active Ceased
- 2013-06-07 KR KR1020157000522A patent/KR20150022996A/ko not_active Application Discontinuation
- 2013-06-07 WO PCT/US2013/044744 patent/WO2013185052A1/en active Application Filing
- 2013-06-07 US US13/912,960 patent/US9770467B2/en active Active
- 2013-06-07 EP EP13799826.6A patent/EP2858722B8/en not_active Not-in-force
-
2015
- 2015-05-21 HK HK15104847.0A patent/HK1204302A1/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JP2015518901A (ja) | 2015-07-06 |
AU2013271375A1 (en) | 2014-12-18 |
US20150010613A1 (en) | 2015-01-08 |
US9770467B2 (en) | 2017-09-26 |
JP6257607B2 (ja) | 2018-01-10 |
NZ702392A (en) | 2017-03-31 |
IN2014MN02492A (zh) | 2015-07-17 |
KR20150022996A (ko) | 2015-03-04 |
CN104507538B (zh) | 2018-04-06 |
EP2858722B8 (en) | 2018-02-21 |
EP2858722A4 (en) | 2015-12-23 |
WO2013185052A1 (en) | 2013-12-12 |
SG10201610251PA (en) | 2017-01-27 |
AU2013271375B2 (en) | 2018-03-22 |
CN104507538A (zh) | 2015-04-08 |
SG11201407875UA (en) | 2014-12-30 |
CA2876150A1 (en) | 2013-12-12 |
EP2858722B1 (en) | 2017-12-13 |
EP2858722A1 (en) | 2015-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272539B (en) | Preparations and methods for immunotherapy | |
IL289821B (en) | Preparations and methods for immunotherapy | |
HK1204302A1 (zh) | 癌症免疫療法的組合物和方法 | |
HK1220387A1 (zh) | 用於免疫療法的組合物和方法 | |
HK1209798A1 (zh) | 用於治療癌症的組合物和方法 | |
EP2593098A4 (en) | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | |
EP2836482A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER | |
EP2890720A4 (en) | COMPOSITIONS AND METHODS OF TREATING CANCER | |
IL285527A (en) | Preparations and methods for immunotherapy | |
EP2854530A4 (en) | COMPOSITIONS AND METHODS FOR BETA-GLUCAN IMMUNOTHERAPY | |
HK1216854A1 (zh) | 用於治療癌症的組合物和方法 | |
EP2841102A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
EP2822593A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
HK1212206A1 (zh) | 用於免疫療法的組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230609 |